Cancer immunotherapy, which harnesses the patient’s own immune system to fight cancer rather than use cytotoxic agents, is considered to be a major breakthrough in cancer therapy.
Our goal is to develop novel immunotherapeutic approaches to treat human disease (e.g. cancer, autoimmune disease, infectious disease, and metabolic disease) by using diverse tools including small molecules, proteins, and engineered immune cells.
- Chimeric Antigen Receptor (CAR)-T cells
Recently, adoptive transfer of CAR-engineered T cells have demonstrated exciting results in clinical trials, and have become a promising therapeutic modality for the treatment of refractory cancer. We are interested in combining different therapeutic approaches, such as merging tumor-targeting small molecules and peptide ligands, tumor infiltrated T cells (TILs), RNA interference, or genome-editing technologies with current T cell engineering technologies.
2. Next Generation Antibody Therapeutics
Several next generation antibody therapeutics, such as antibody drug conjugates (ADCs) and bispecific antibodies (BsAbs), have been recently approved for cancer treatment. We are interested in developing next generation antibody therapeutics with novel scaffolds that allows to overcome the shortcomings of current formats, as well as with novel mode of actions.
3. Immunomodulatory Small Molecule Drugs
Small molecule cancer drugs play important roles as a first-line therapy in current cancer treatment regimen. However, most of the small molecule cancer drugs are also toxic to normal cells to some extent, which results in serious systemic toxicity in patients. Therefore, it is highly desirable to develop small molecule-based therapies with novel modes of action to overcome such drawbacks.